BR9913635A - Processos e composições para modulação da interação entre o receptor de apj e o vìrus hiv - Google Patents

Processos e composições para modulação da interação entre o receptor de apj e o vìrus hiv

Info

Publication number
BR9913635A
BR9913635A BR9913635-0A BR9913635A BR9913635A BR 9913635 A BR9913635 A BR 9913635A BR 9913635 A BR9913635 A BR 9913635A BR 9913635 A BR9913635 A BR 9913635A
Authority
BR
Brazil
Prior art keywords
modulating
interaction
compositions
processes
hiv virus
Prior art date
Application number
BR9913635-0A
Other languages
English (en)
Inventor
Robert Doms
Daryl Faulds
Joseph E Hesselgesser
Richard Horuk
Branislava Mitrovic
Yiqing Zhou
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR9913635A publication Critical patent/BR9913635A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"PROCESSOS E COMPOSIçõES PARA MODULAçãO DA INTERAçãO ENTRE O RECEPTOR DE APJ E O VìRUS HIV"<D>. O receptor órfão transmembrana de sete domínios, APJ, pode funcionar como um co-receptor para infecção celular pelo vírus HIV. O estabelecimento de linhagens de célula que co-expressam CD4 e APJ fornecem ferramentas valiosas para continuar a pesquisa sobre infecção por HIV e o desenvolvimento de anti-HIV terapêuticos.
BR9913635-0A 1998-09-08 1999-09-07 Processos e composições para modulação da interação entre o receptor de apj e o vìrus hiv BR9913635A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/149,045 US6475718B2 (en) 1998-09-08 1998-09-08 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
PCT/EP1999/006553 WO2000014220A1 (en) 1998-09-08 1999-09-07 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus

Publications (1)

Publication Number Publication Date
BR9913635A true BR9913635A (pt) 2001-05-22

Family

ID=22528559

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913635-0A BR9913635A (pt) 1998-09-08 1999-09-07 Processos e composições para modulação da interação entre o receptor de apj e o vìrus hiv

Country Status (14)

Country Link
US (5) US6475718B2 (pt)
EP (1) EP1109906A1 (pt)
JP (1) JP2002532061A (pt)
KR (1) KR20020013467A (pt)
AU (1) AU767484B2 (pt)
BR (1) BR9913635A (pt)
CA (1) CA2341782A1 (pt)
HU (1) HUP0103768A3 (pt)
IL (1) IL141452A0 (pt)
NO (1) NO20011162D0 (pt)
PL (1) PL346564A1 (pt)
RU (1) RU2225721C2 (pt)
SK (1) SK3082001A3 (pt)
WO (1) WO2000014220A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403447A1 (en) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Peptide derivative
AU2001264937A1 (en) * 2000-05-23 2001-12-03 Genaissance Pharmaceuticals, Inc. Haplotypes of the agtrl1 gene
WO2006023893A2 (en) * 2004-08-23 2006-03-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis and apoptosis with apelin compositions
JP4954326B2 (ja) 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP4231014A3 (en) * 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CA2851397C (en) * 2011-12-16 2020-03-10 Cargill, Incorporated Environmentally-friendly improved deicer compositions
BR112015020587A2 (pt) 2013-03-14 2017-10-10 Regeneron Pharma proteínas de fusão de apelina e suas utilizações
AU2014352962B2 (en) 2013-11-20 2019-11-07 Regeneron Pharmaceuticals, Inc. APLNR modulators and uses thereof
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
BR112017014067B1 (pt) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975749A2 (en) 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same

Also Published As

Publication number Publication date
IL141452A0 (en) 2002-03-10
EP1109906A1 (en) 2001-06-27
KR20020013467A (ko) 2002-02-20
NO20011162L (no) 2001-03-07
US6475718B2 (en) 2002-11-05
JP2002532061A (ja) 2002-10-02
US20030008391A1 (en) 2003-01-09
HUP0103768A2 (hu) 2002-02-28
AU5973799A (en) 2000-03-27
US20030008279A1 (en) 2003-01-09
AU767484B2 (en) 2003-11-13
SK3082001A3 (en) 2001-09-11
NO20011162D0 (no) 2001-03-07
US20020062488A1 (en) 2002-05-23
PL346564A1 (en) 2002-02-11
RU2225721C2 (ru) 2004-03-20
CA2341782A1 (en) 2000-03-16
US20030003447A1 (en) 2003-01-02
WO2000014220A1 (en) 2000-03-16
US20030008376A1 (en) 2003-01-09
HUP0103768A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
BR9913635A (pt) Processos e composições para modulação da interação entre o receptor de apj e o vìrus hiv
BR0215050A (pt) Compostos heterocìclicos de ligação a receptor de quimiocina com eficácia realçada
BR9810857A (pt) Composto quìmico, processos para a preparação do mesmo, e para a preparação de uma poliolefina, sistema catalisador, e, uso do mesmo
BR0207543A (pt) Quinolinona tricìclica e quinolina tricìclica como compostos moduladores de receptor de androgênio
ECSP045133A (es) Benzoxazoles sustituidos y análogos como agentes estrogenicos
HRP20050845A2 (en) Prostaglandin analogs as ep4 receptor antagonists
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
ES2153964T3 (es) Liberacion controlada de farmacos administrados por via sublingual o bucal.
PE20100736A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen
CU23282A3 (es) DERIVADOS DEL TROPANO ÃsTILES EN TERAPIA
BR9808588A (pt) Ecteinascidinas e ecteinascidinas de n-óxido substituìdas por nucleófilo
WO2004037784A3 (en) Pyrrolidones with anti-hiv activity
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
UY25113A1 (es) Composiciones parenterales de alatrofloxacino
BR0000544A (pt) Poliolefinas de metaloceno estabilizadas
ES2173652T3 (es) Procedimiento para la firma digital de un mensaje.
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
DE69917278D1 (de) Heterocyclyl sulphonamid derivate
ATE429793T1 (de) Dienstestromsteuerung
DE69800699T2 (de) Verbindungen
BR9915544A (pt) Derivados de 2-hetaril-3,4-dihidro-2h-pirrol
ES2191058T3 (es) Celulas portadoras de receptores simulados de cd4, y moleculas y metodos relacionados.
BR9910305A (pt) Vacina
ES2137378T3 (es) Estructuras peptidicas poliramificadas para ser utilizadas contra el hiv.
DE59902180D1 (de) Inhibierung von cd95-unabhängiger apoptose bei aids

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.